Bloomberg Law reports Lilly has widened its legal push against sellers of knockoff versions of its experimental obesity drug, which is still unapproved.
Recap by typeshit. Post by Bloomberg Law on X.
A lawyer named Jeff walks through how his side argues Ozempic, Wegovy and other semaglutide drugs may be linked to NAION, a serious form of sudden vision loss.
Stavros Nicolaou of the Pharmaceutical Task Group wants police to act. SAHPRA says it has seized products and opened criminal cases.
The physician group is pushing back on an FDA plan that would open interim access to unapproved peptides, and wants the White House to block it.
Investigators turned up a warehouse of empty pens and a farm building used as a drug factory, as counterfeit weight loss injection sellers grow more organized.
The Hill looks at how pairing a GLP-1 drug with other treatment could bring added benefits for people living with psoriasis.
Ravikiran Bodlapati and Frank Burslem argue eligibility, access and uptake will decide how far GLP-1 sales can grow from today.
Loading…